Loading…
← CockpitCompetitor Analysis › AMLX Amylyx Pharmaceuticals, Inc.Open in the cockpit ↗

Amylyx Pharmaceuticals, Inc.AMLXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech that withdrew its ALS drug Relyvrio in 2024 and pivoted pipeline toward avexitide for hypoglycemia disorders.

Momentum leader 98
Mkt cap
$3.42B
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$40.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
111 days
9 Mar 2027
Close · USD$26.62
1D-3.3%
1W-16.3%
1M-7.5%
3M+63.5%
6M+92.8%
YTD+120.4%
1Y+100.9%
ATR %6.8%
Beta1.01
52w lowhigh16.5% off high

What Amylyx Pharmaceuticals does

Biotech that withdrew its ALS drug Relyvrio in 2024 and pivoted pipeline toward avexitide for hypoglycemia disorders.

Has no product on sale since it withdrew Relyvrio, its ALS drug, so it earns no product revenue and lives on cash from that drug's earlier sales. Its spending now goes to avexitide, a drug aimed at dangerously low blood sugar after weight-loss surgery.

Products and services

  • Avexitide (hypoglycemia)
  • Legacy Relyvrio/Albrioza (withdrawn)

Where it sits in the supply chain

  • Biopharma R&D
  • Neurodegenerative/metabolic drug…
  • Post-Relyvrio pipeline pivot

What could go right

  • Avexitide approval/launch
  • Orphan-disease pricing potential

What could go wrong

  • Reputational hit from Relyvrio withdrawal
  • Single-asset pipeline concentration

Moat: none (IP / patents). Lost its only approved product; must re-prove itself with a new pipeline.

Headquarters: Cambridge, Massachusetts, US · Founded: 2019 · Employees: 136

Named competitors

Amylyx Pharmaceuticals at a glance

Size Amylyx Pharmaceuticals (AMLX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.42B, the 1446th largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.62 on 18 Nov 2026.

Performance Over six months the shares gained 92.8%, against +3.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth Revenue grew 100.0% over the last twelve months (peer median +3.6%).

Short interest Short interest is 10.0% of the free float (30 Oct 2026).

Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026AMLX 197Peer median 104
Six months, rebased to 100: Amylyx Pharmaceuticals against the median of its 20 peers (local-currency closes).

Amylyx Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$87.4M$381M$22.2M
Revenue growth—-100%-77%+1,613%—
Gross profit-$282,000-$525,000-$38.2M$354M$18.8M
EBITDA-$175M-$153M-$255M$39.9M-$201M
Net income-$163M-$145M-$302M$49.3M-$198M
Free cash flow-$130M-$123M-$168M$10.7M-$182M
Capital expenditure$4.14M$138,000$36.4M$1.24M$2.53M
Total debt$4.94M$5.96M$1.98M$4.24M$6.28M

Quarterly statements and history in the cockpit →

Amylyx Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%+40%VRDN2096PPLPHARMA000739002262688180ARQTACUTAASVKTXSFZNWOCKPHARMA600511SLSXENE1513AMLX6-month return →1-month return →
Up and to the right = strong over both horizons. Amylyx Pharmaceuticals is the large dot.

Amylyx Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (AMLX vs ZEAL.CO vs RZLT vs AMGN)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Amylyx Pharmaceuticals AMLX$3.42B+93%+100%n/an/an/a
Zealand Pharma A/S ZEAL.CO$2.16B-30%-50%46%0.4×n/a
Rezolute RZLT$411M+32%n/an/an/an/a
Amgen AMGN$240B+34%+9%36%7.2×1.6%

How Amylyx Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Amylyx Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureAMLXPeer medianRank in peer set
1-month return-7.5%+2.9%4th lowest of 21
6-month return+92.8%+3.4%2nd highest of 20
Distance from 52-week high-16.5%-22.7%10th highest of 21
Revenue growth (TTM)+100.0%+3.6%highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%106.6×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%2.6×-3.4%+10.6%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%3.8×n/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%2.5×4.7%+4.5%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%3.1×-2.1%+12.0%
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%8.1×n/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%6.6×49.2%+367.3%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%20.4×n/an/a
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%2.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%9.3×58.0%+4.2%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%0.6×-4.9%+7.8%
China National Medicines 600511.SSChina$3.26B+3%+3%4%0.3×-10.0%+5.4%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%3.2×6.4%+5.9%
Organon & OGNUnited States$3.66B+3%-3%20%1.8×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%2.2×-7.5%-9.6%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%2.3×-7.0%+2.0%

Questions

Who are Amylyx Pharmaceuticals's main competitors?
Named competitors: Zealand Pharma (ZEAL.CO), Rezolute (RZLT), Amgen (AMGN). The cockpit's measured peer set (industry) also includes Viridian Therapeutics (VRDN), Simcere Pharmaceutical (2096.HK), Piramal Pharma (PPLPHARMA.NS), Apeloa Pharmaceutical (000739.SZ), Jiangsu Nhwa Pharmaceutical (002262.SZ), Shanghai Junshi Biosciences (688180.SS).
How has Amylyx Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +92.8% against +3.4% for the median peer; over one year +100.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.